Compare PRAX & U Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | U |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 8.0B |
| IPO Year | 2020 | 2020 |
| Metric | PRAX | U |
|---|---|---|
| Price | $282.31 | $27.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 21 |
| Target Price | ★ $572.13 | $36.61 |
| AVG Volume (30 Days) | 475.2K | ★ 8.9M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.86 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,849,648,000.00 |
| Revenue This Year | N/A | $15.81 |
| Revenue Next Year | $7,758.26 | $12.93 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 2.01 |
| 52 Week Low | $37.25 | $16.78 |
| 52 Week High | $366.52 | $52.15 |
| Indicator | PRAX | U |
|---|---|---|
| Relative Strength Index (RSI) | 47.14 | 49.27 |
| Support Level | $238.77 | $24.45 |
| Resistance Level | $342.62 | $29.96 |
| Average True Range (ATR) | 21.47 | 1.64 |
| MACD | 0.62 | -0.32 |
| Stochastic Oscillator | 39.34 | 27.27 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run, and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC, and other Americas, and key revenue is derived from the EMEA region. Its products are used in the gaming industry, retail, automotive, architecture, engineering, and construction.